These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340 [TBL] [Abstract][Full Text] [Related]
10. Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors. Hsieh TH; Liu YR; Chang TY; Liang ML; Chen HH; Wang HW; Yen Y; Wong TT Neuro Oncol; 2018 Mar; 20(4):519-530. PubMed ID: 29036598 [TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications. Kalavska K; Conteduca V; De Giorgi U; Mego M Curr Cancer Drug Targets; 2018; 18(10):967-978. PubMed ID: 29295694 [TBL] [Abstract][Full Text] [Related]
12. Current pharmacotherapy for testicular germ cell cancer. Alsdorf W; Seidel C; Bokemeyer C; Oing C Expert Opin Pharmacother; 2019 May; 20(7):837-850. PubMed ID: 30849243 [TBL] [Abstract][Full Text] [Related]
13. Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors. Cavallo F; Feldman DR; Barchi M Int J Dev Biol; 2013; 57(2-4):273-80. PubMed ID: 23784838 [TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments. Oing C; Seidel C; von Amsberg G; Oechsle K; Bokemeyer C Expert Opin Pharmacother; 2016; 17(4):545-60. PubMed ID: 26630452 [TBL] [Abstract][Full Text] [Related]
15. Re: Understanding the Crosstalk of Molecular Factors and Signaling Pathways Reveals Novel Biomarkers of Cisplatin Resistance in Testicular Germ Cell Tumors. Richie JP J Urol; 2020 Jul; 204(1):187. PubMed ID: 32240026 [No Abstract] [Full Text] [Related]
16. Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours. Cierna Z; Miskovska V; Roska J; Jurkovicova D; Pulzova LB; Sestakova Z; Hurbanova L; Machalekova K; Chovanec M; Rejlekova K; Svetlovska D; Kalavska K; Kajo K; Babal P; Mardiak J; Ward TA; Mego M; Chovanec M BMC Cancer; 2020 Jan; 20(1):17. PubMed ID: 31906898 [TBL] [Abstract][Full Text] [Related]
17. [Results of the German studies (MAHO) for treatment of testicular germ cell tumors in children--an update]. Schmidt P; Haas RJ; Göbel U; Calaminus G Klin Padiatr; 2002; 214(4):167-72. PubMed ID: 12165897 [TBL] [Abstract][Full Text] [Related]
19. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. de Vries G; Rosas-Plaza X; van Vugt MATM; Gietema JA; de Jong S Cancer Treat Rev; 2020 Aug; 88():102054. PubMed ID: 32593915 [TBL] [Abstract][Full Text] [Related]
20. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. Fenner M; Oing C; Dieing A; Gauler T; Oechsle K; Lorch A; Hentrich M; Kopp HG; Bokemeyer C; Honecker F J Cancer Res Clin Oncol; 2019 Mar; 145(3):717-723. PubMed ID: 30232558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]